
## Knud Bendix

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5526848/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	High intratumoural galectinâ€1 expression predicts adverse outcome in ALK â^' ALCL and CD30 + PTCLâ€NOS. Hematological Oncology, 2020, 38, 59-66.	1.7	6
2	Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified. Blood Advances, 2018, 2, 2533-2542.	5.2	8
3	DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood, 2017, 130, 554-557.	1.4	110
4	Tumourâ€associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumourâ€infiltrating inflammatory cell subsets and outcome. European Journal of Haematology, 2016, 96, 252-259.	2.2	39
5	Post-transplant lymphoproliferative disorder following kidney transplantation: a population-based cohort study. Transplant International, 2016, 29, 483-493.	1.6	20
6	High Intratumoral Expression of Galectin-1 Correlates with Superior Outcome in HIV-Associated DLBCL. Blood, 2016, 128, 4142-4142.	1.4	0
7	Differential protein expression of peroxiredoxinâ€l in classical Hodgkin Lymphoma: a possible correlation to clinical behaviour. Hematological Oncology, 2015, 33, 253-255.	1.7	2
8	Relationship of intratumoural protein expression patterns to age and <scp>E</scp> psteinâ€ <scp>B</scp> arr virus status in classical <scp>H</scp> odgkin lymphoma. European Journal of Haematology, 2015, 95, 137-149.	2.2	8
9	HLA Associations and Risk of Posttransplant Lymphoproliferative Disorder in a Danish Population-Based Cohort. Transplantation Direct, 2015, 1, e25.	1.6	4
10	Evaluation of clinical trial eligibility and prognostic indices in a populationâ€based cohort of systemic peripheral Tâ€cell lymphomas from the Danish Lymphoma Registry. Hematological Oncology, 2015, 33, 120-128.	1.7	15
11	Stereological Quantification of Immune-Competent Cells in Baseline Biopsy Specimens From Achilles Tendons. American Journal of Sports Medicine, 2014, 42, 2435-2445.	4.2	64
12	Acute renal failure and normal blood count: A rare presentation of T-cell acute lymphoblastic leukemia. Leukemia Research Reports, 2014, 3, 14-16.	0.4	4
13	Identification of a Subset of Peripheral T-Cell Lymphoma, Not Otherwise Specified, Characterized By FOXP3-Positive Regulatory T-Cell Phenotype, HTLV-1 Negativity and Poor Outcome. Blood, 2014, 124, 1616-1616.	1.4	1
14	Tumor Microenvironmental Features and Outcome in Post-Transplant Lymphoproliferative Disorder. Blood, 2014, 124, 1617-1617.	1.4	1
15	Proteomic Analysis Identifies Outcome-Predictive Clusters in Patients with Peripheral T-Cell Lymphoma, Not Otherwise Specified. Blood, 2014, 124, 1623-1623.	1.4	0
16	Clinical Outcome Determinants for Sequentially Transformed Indolent Lymphomas Treated with or without Autologous Stem Cell Transplantation. Blood, 2014, 124, 1194-1194.	1.4	0
17	Epstein-Barr Virus Status Correlates with Composition and Prognostic Impact of the Tumor Microenvironment in Classical Hodgkin Lymphoma. Blood, 2012, 120, 52-52.	1.4	0
18	Chronic Myeloid Leukemia Presenting with Isolated Thrombocythemia: A Case Revealing Its Stem Cell Biology. Blood, 2012, 120, 4427-4427.	1.4	1

KNUD BENDIX

#	Article	IF	CITATIONS
19	Digital Pathology for the Assessment of Tissue Microarrays in Peripheral T-Cell Lymphomas. Blood, 2012, 120, 1584-1584.	1.4	0
20	Different Cytogenetic Patterns in Specified Categories of Secondary AML: Results of a Population-Based Registry Study,. Blood, 2011, 118, 3586-3586.	1.4	0
21	Development of a Splenic Marginal Zone Lymphoma Associated with Active Chronic Visceral Leishmaniasis. Blood, 2011, 118, 5202-5202.	1.4	0
22	Malignant Lymphoma and Breast Implants: a Case of Diffuse Large B-Cell Lymphoma (DLBCL) with Implant-near Relapse Localization. Blood, 2010, 116, 5103-5103.	1.4	4
23	Posttransplant Lymphoproliferative Disorders (PTLD) After Renal Transplantation: Focus on HLA Antigens. Blood, 2010, 116, 5074-5074.	1.4	1
24	Hepatotoxicity in Patients Treated with Gemtuzumab Ozogamicin - Specific Targeting of Hepatocytes?. Blood, 2009, 114, 4150-4150.	1.4	8
25	Impaired CD163 Mediated Hemoglobin-Scavenging and Hemolytic Crisis in Patients Treated with CD33 Targeted Chemotherapy (Gemtuzumab Ozogamicin, Mylotargâ,,¢) Blood, 2007, 110, 3684-3684.	1.4	0
26	Correlation between Intratumoral Cellular Microenvironment, Clinicopathological Parameters and Prognosis in Hodgkin Lymphoma Blood, 2007, 110, 2273-2273.	1.4	0
27	Expression Pattern and Prognostic Impact of Vascular Endothelial Growth Factors VEGF and VEGF-C and Their Receptors Flt-1, KDR and Flt-4 in Peripheral T-Cell Lymphomas Blood, 2007, 110, 689-689.	1.4	0
28	A Single-Centre Experience of Clinico-Pathological Features, Risk Factors and Treatment Outcome of Posttransplant Lymphoproliferative Disorders (PTLD) after Renal Transplantation Blood, 2007, 110, 4421-4421.	1.4	0
29	Expression Level, Tissue Distribution Pattern and Prognostic Impact of Vascular Endothelial Growth Factor (VEGF) and Its Receptors Flt-1 and KDR in Different Subtypes of Non-Hodgkin Lymphoma (NHL) Blood, 2005, 106, 2824-2824.	1.4	1
30	A Multiplex PCR for Detection of Genetic Aberrations in Non-Hodkin's Lymphoma Blood, 2004, 104, 4554-4554.	1.4	0
31	Bone Marrow Pathology. European Journal of Haematology, 2002, 68, 125-125.	2.2	0
32	Sealing effect of hydroxyapatite coating: A 12-month study in canines. Acta Orthopaedica, 2000, 71, 563-573.	1.4	39
33	Relevance of <i>in Vitro</i> Leukaemia Cell Survival to Short- and Long Term Clinical Outcome in AML. Leukemia and Lymphoma, 1999, 32, 327-337.	1.3	7